Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.

ABSTRACT: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm with a prevalence of 4 to 6 per 100,000 people in the USA. Treatment recommendations are risk-adapted. This study was conducted to evaluate how physicians risk-stratify patients at the time of MF diagnosis, the accuracy of the risk stratification, and its effect on treatment selection. Medical charts were reviewed at US community hematology/oncology practices in the Cardinal Health Oncology Provider Extended Network; patient clinical characteristics, risk stratification, and treatment data were collected. Physician-assigned risk categorizations were compared with data-derived risk categorizations based on the International Prognostic Scoring System, the system recommended at diagnosis. A total of 491 patients diagnosed with MF bet

SUBMITTER: Verstovsek S 

PROVIDER: S-EPMC7536164 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature